1	Antiemetic effect of pregabalin in breast reconstruction surgery in						
2	patients after bariatric surgery: Prospective, randomized, double-blind						
3	study						
4							
5	Effect of pregabalin on postoperative nausea and vomiting						
6							
7	Rafael Reis Fernandes¹¹⁺, Marcello Fonseca Salgado-Filho²୩, Guilherme Bracco						
8	Graziosi <sup>3&amp;</sup> , André Luiz Viana Nery da Silva <sup>3&amp;</sup> , Flávio Augusto Amaral Fernandes Távora <sup>3&amp;</sup> ,						
9	Caio Pontes de Azevedo <sup>4&amp;</sup> , Alice Ramos Oliveira da Silva <sup>5&amp;</sup> , Nubia Verçosa <sup>6¶</sup> , Ismar Lima						
10	Cavalcanti <sup>1¶</sup>						
11							
12							
13 14 15 16 17	<b>1</b> Department of General and Specialized Surgery, Graduate Program in Medical Sciences, Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.						
	<b>2</b> Graduate Program in Anesthesia for High-Complexity Surgery, Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.						
19 20	3 Nery-Graziosi Plastic Surgery, Niterói, Rio de Janeiro, Brazil.						
20 21 22	4 Anesthesiologist, Niterói, Rio de Janeiro, Brazil.						
23 24	5 School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.						
25 26 27 28	<b>6</b> Department of Surgery, Graduate Program in Surgical Sciences, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.						
29							
30	*Corresponding author						
31	Email: <u>rafareis.rs@icloud.com</u> (RRF).						
32	¶ These authors also contributed to this study.						
33							

34 NOTE: These authors also contributed a should be the thinest up be review and should not be used to guide clinical practice.

## 35 Abstract

36

### 37 Introduction

38 Postoperative nausea and vomiting (PONV) is a common complication after general anesthesia.

- 39 Pregabalin may reduce its incidence. The objective of this study was to evaluate the adjuvant
- 40 antiemetic effect of pregabalin in the first 24 hours after surgery in patients undergoing breast
- 41 reconstruction after bariatric surgery.

## 42 Materials and Methods

43 This prospective, randomized, double-blind study had 52 female patients aged between 18 and 44 64 years with physical status 1-2 of the American Society of Anesthesiologists who underwent 45 breast reconstruction after bariatric surgery. The patients were divided into two groups. Patients 46 in the control group received placebo, and those in the pregabalin group received 75 mg of 47 pregabalin 2 hours before surgery and 75 mg 12 hours later. All patients received 4 mg 48 dexamethasone and 4 mg ondansetron. The incidence of PONV was evaluated in the immediate 49 postoperative period and 6 hours, 12 hours, and 24 hours later. The need for rescue doses of 50 antiemetics and adverse events in the first 24 hours were recorded.

## 51 Results

The groups were homogeneous in clinical and treatment variables. There was no significant difference in the incidence of PONV over time in the control group (P = 0.71/no occurrence) or in the pregabalin group (P = 0.11/P = 0.26). There was no significant difference in the need for rescue antiemetic dose (P = 0.40) or in the incidence of adverse events (P = 0.51) between groups.

#### 57 Conclusion

The administration of pregabalin in the first 24 hours after surgery did not significantly reduce
 PONV in patients undergoing breast reconstruction after bariatric surgery.

60

61

# 62 Introduction

63 Postoperative nausea and vomiting (PONV) is common after general anesthesia, with an 64 incidence ranging from 30 to 50% [1]. Thus, prevention measures are routinely taken during 65 anesthetic-surgical procedures, especially those performed under general anesthesia using 66 opioids, inhalational anesthetics, or nitrous oxide [1,2]. The goals of preventive treatment for 67 PONV are to avoid unexpected hospitalizations, delays in hospital discharge, increases in 68 hospital costs, and patient discomfort and dissatisfaction [3,4]. Therefore, an aggressive and 69 multimodal prophylactic approach is recommended, especially in high-risk patients. These high-70 risk patients are classified using the simplified Apfel score [2,5,6]. Recently, GABAergic adjuvants 71 such as pregabalin have been associated with multimodal management for better control of 72 PONV [1,7].

We hypothesized that patients who were preventively medicated with pregabalin would have a lower rate of nausea and vomiting in the first 24 postoperative hours. The objective of this study was to evaluate the antiemetic effect of pregabalin in the first 24 hours after surgery in patients undergoing breast reconstruction after bariatric surgery under general anesthesia.

77

#### 78 Materials and Methods

79 After approval by the Ethics Committee in Human Research of the Antônio Pedro University 80 Hospital, Niterói, Rio de Janeiro, Brazil, on November 13, 2018 (CAAE: 85415718.2.0000.5243) 81 and registration in the Brazilian Clinical Trials Registry (ReBEC – UTN: U1111-1259-6153), a 82 prospective, randomized, double-blind, placebo-controlled, single-center clinical trial with 52 adult 83 patients undergoing elective breast reconstruction after bariatric surgery under general 84 anesthesia in a tertiary hospital between August 2019 and July 2021 was conducted. All patients 85 signed a written informed consent form before surgery. This manuscript follows the guidelines of 86 CONSORT.

The inclusion criteria were 52 female patients aged between 18 and 64 years, with physical status classified by the American Society of Anesthesiologists (ASA) scale 1 and 2 [8], who underwent breast reconstruction after bariatric surgery. The exclusion criteria were patients who had participated in another study in the last month; smokers; alcohol drinkers; body mass index greater than 35 mg/m<sup>2</sup>; occurrence of episodes of nausea or vomiting in the 24 hours before surgery; use of corticosteroids; use of psychoactive drugs or any drug with an antiemetic effect; known hypersensitivity to any study medication; patients with severe kidney, liver, lung, heart,

94 brain, or bone marrow diseases; and patients who had a history of uncontrollable vomiting even
95 after administration of rescue medication.

96 No patient received any premedication. In the operating room, the patients were 97 monitored with pulse oximetry, noninvasive blood pressure, electrocardioscopy, capnography, 98 and degree of neuromuscular blockade. A 20-G intravenous cannula was inserted into the right 99 or left arm. Preoxygenation was performed with 100% oxygen for 5 minutes at 6 L min<sup>-1</sup> using a 100 face mask. Both groups underwent the same general anesthesia. Anesthesia was induced with 101 intravenous administration of 1.5 mg.kg<sup>-1</sup> fentanyl (Cristália®, São Paulo, Brazil) 3 mcg·kg<sup>-1</sup>, 102 lidocaine (Cristália<sup>®</sup>, São Paulo, Brazil), 1-2 mg·kg<sup>-1</sup> propofol (Cristália<sup>®</sup>, São Paulo, Brazil), and 103 0.6 mg·kg<sup>-1</sup> rocuronium bromide (Cristália<sup>®</sup>, São Paulo, Brazil) followed by orotracheal intubation. 104 Anesthesia was maintained with inhalation of sevoflurane (Cristália®, São Paulo, Brazil) at a 2% 105 end-tidal concentration combined with 50% oxygen/compressed air at 1 L min-1 and 0.05 to 0.3 106 mcg·kg<sup>-1</sup>·min<sup>-1</sup> remifentanil (GSK<sup>®</sup>, Rio de Janeiro, Brazil) intravenously by an infusion pump (B. 107 Braun<sup>®</sup>, Rio de Janeiro, Brazil) when necessary. The patients received perioperative preventive 108 analgesia with the nonsteroidal anti-inflammatory drug parecoxib sodium (Pfizer®, São Paulo, 109 Brazil) 40 mg intravenously and dipyrone sodium (Sanofi Aventis<sup>®</sup>, São Paulo, Brazil) 50 mg kg<sup>-</sup> 110 <sup>1</sup> intravenously. For perioperative preventive antiemesis, the patients received 4 mg intravenous 111 ondansetron (Cristália<sup>®</sup>, São Paulo, Brazil) and 4 mg intravenous dexamethasone (Aché<sup>®</sup>, São 112 Paulo, Brazil). At the end of surgery, 2 mg·kg<sup>-1</sup> of sugammadex (MSD<sup>®</sup>, São Paulo, Brazil) was 113 administered intravenously to reverse the neuromuscular block, and the trachea was extubated. 114 Postoperative analgesia was administered with 50 mg·kg<sup>-1</sup> intravenous dipyrone (Sanofi Aventis<sup>®</sup>, 115 São Paulo, Brazil) every 4 hours and 40 mg intravenous parecoxib sodium (Pfizer®, São Paulo, 116 Brazil) every 12 hours in regular doses and 10 mg intravenous nalbuphine hydrochloride 117 (Cristália®, São Paulo, Brazil) as a rescue dose every 4 hours when the visual analog scale (VAS) 118 was greater than 4 (moderate pain) or when requested by the patient due to uncontrolled pain. 119 Postoperative antiemesis was performed with rescue doses of 4 mg ondansetron (Cristália®, São 120 Paulo, Brazil) every 8 hours, as requested by the patient and after nausea or vomiting.

121 The primary outcome of the study was the antiemetic effect of pregabalin. The frequency 122 and intensity of individual episodes of nausea and the frequency of vomiting immediately, 6 hours, 123 12 hours, and 24 hours after surgery were compared. The secondary outcomes of the study were

the rating of pain by VAS at rest and on movement at the same four times, the amounts of antiemetic and analgesic rescue medications used in the first 24 postoperative hours, the need for opioid medication after hospital discharge, chronic pain 3 months after surgery [9], and the incidence of adverse events in the first 24 postoperative hours.

For the purpose of this study, nausea was defined as a subjective unpleasant and involuntary sensation of the urge to vomit, without the expulsion of stomach contents, and vomiting was defined as the expulsion of stomach contents through the mouth [1].

131 Patients from both groups were evaluated at four times during the first 24 hours 132 postoperatively, immediately, 6 hours, 12 hours, and 24 hours, to record PONV onset, pain at rest 133 or movement according to the VAS, the need for antiemetic and/or analgesic rescue medication, 134 and the occurrence of adverse events. The rescue doses of nalbuphine in the first 24 hours, the 135 consumption of remifentanil during the perioperative period, and the need for opioid use after 136 hospital discharge were compared between the groups to evaluate the opioid-sparing effect of 137 pregabalin. Three months after hospital discharge, all patients were contacted by telephone to 138 evaluate postoperative chronic pain.

139 A protocol form was used to record the data. It contained the patient's medical record 140 number, initials, age, anthropometric data, previous pathological history, physical status 141 according to the ASA [8], total procedure time, total anesthesia time, total waking time (which was 142 the time between interruption of anesthesia and extubation), amount of fluids administered, and 143 the Aldrete and Kroulik scale [10] of postanesthetic recovery. The frequency of PONV at each 144 time, as well as pain, according to the VAS, during the rest period and during movement after 145 surgery were also recorded in the protocol form. The antiemetic and analgesic rescue medications 146 used in the first 24 postoperative hours, the opioid sparing effect through quantification of the 147 rescue doses of nalbuphine hydrochloride in the first 24 hours, the consumption of remifentanil in 148 the perioperative period and the need for opioids after hospital discharge, the evaluation of the 149 development of chronic pain after 3 months postoperatively, and the occurrence of adverse 150 events in the first 24 hours were recorded.

# 151 Statistical analysis

152 To calculate the sample size and power of the study, Grant et al. [1], who performed a 153 meta-analysis on pregabalin reducing PONV, obtained a 53% reduction in the incidence of PONV

in the group that used pregabalin. Thus, to calculate a 53% reduction in PONV cases with a study
power of 90%, with an alpha value less than 0.05 and a beta value less than 0.2, 24 patients were
required in each group. An additional 10% was included to cover possible case losses, for a total
of 52 patients. GraphPad Prism QuickCalcs<sup>®</sup> software (Inc., La Jolla, CA, USA) was used for this
calculation.

159 After electronic randomization (Randomized ®), the patients were divided into two groups 160 of 26 in a 1:1 ratio: the control group and the pregabalin group. The compounding pharmacy of 161 the hospital formulated a placebo capsule consisting of starch and another capsule of 75 mg of 162 pregabalin. The pharmacist allocated the tablets (placebo or pregabalin) into envelopes of 163 identical appearance, numbered from 1 to 52, following randomization principles. Each envelope 164 contained two placebo tablets or two pregabalin tablets. One tablet was given to the patient 2 165 hours before surgery in the preoperative period and one tablet 12 hours later. The researcher and 166 the patient were blinded to the pills administered.

167 For descriptive analysis, we organized the observed data into tables, and they are 168 expressed as measures of central tendency and dispersion suitable for numerical data and as 169 frequency and percentage for categorical data.

170 The inferential analysis consisted of the following methods: Clinical and treatment 171 variables were compared between groups (placebo and pregabalin) using the independent-172 sample Student's t test (parametric) or the Mann–Whitney test (nonparametric) for numerical data. 173 and the  $\chi^2$  test or Fisher's exact test for categorical data. Repeated-measures analysis of variance 174 (ANOVA) was run on categorical data using the CATMOD procedure [11] of SAS® statistical 175 software to verify whether there was significant variation in nausea or vomiting over the four time 176 points. The longitudinal analysis of VAS over the four time points was composed of repeated-177 measures ANOVA within each group. Repeated-measures ANOVA with one factor, highlighting 178 the interaction component (time × group), was done to compare the evolution of VAS between 179 the groups. The Bonferroni test of multiple comparisons was applied to identify which times 180 differed significantly from each other within each group.

181 The Shapiro–Wilk test was run to see if each variable conformed to the normal 182 distribution, together with the graphical analysis of the histograms. The level of significance

- adopted was 5%. Statistical analysis was performed with SPSS statistical software version 26
- 184 and SAS<sup>®</sup> 6.11 (SAS Institute, Inc., Cary, NC).

# 185 Results

186 A total of 52 eligible female patients were recruited and randomized into two groups: 26 to

the control group and 26 to the pregabalin group (Fig. 1). All included patients were allocated to

a group. There was no loss in the analyses, and there was no loss to follow-up.



- There was no significant difference at the 5% level between the groups in the clinical variables or the characteristics of surgery between the groups. Demographic data were homogeneous, except for height, but this had no clinical significance (Table 1). There was no significant difference in the use of opioids in the perioperative period.
- 224
- 225 Table 1. Demographic data, surgery characteristics and perioperative use of opioids
- 226

Variable	Р	regabalin	Placebo	P value
Demographic data				
Age (years)		35.8 <u>+</u> 8.6	37.6 <u>±</u> 8.0	0.45
Weight (kg)		70.9 <u>+</u> 8.8	66.1 <u>+</u> 9.3	0.061
Height (m)		<b>1.65</b> 0.06	<b>1.62</b> <u>+</u> 0.06	0.038
IMC (kg/m²)		26.0 <u>±</u> 3.0	25.2 <u>+</u> 2.8	0.33
Surgery characteristic				
Total surgery time (min)		176 <u>+</u> 31	168 <u>+</u> 39	0.46
Total anesthesia time (min)		222 <u>+</u> 33	212 <u>+</u> 40	0.29
Wake-up time (min)		15.5 <u></u> 5.9	13.3 <u>+</u> 4.0	0.13
Fluids (ml)		1229 <u>+</u> 221	1208 <sub>±</sub> 230	0.74
Perioperative opioid dose				
Total opioid rescue	1	0 - 1	0 0 - 1	0.69
Total remifentanil (mcg)	200	155 _ 394	245 87 <u>3</u> 61	0.64
Total fentanyl (mcg)	200	175 _ 225	175 175 200	0.063

BMI: body mass index. Data are expressed as the mean ± standard deviation and were compared using Student's *t* test for independent samples. Nonnormal data are expressed as the median and interquartile range (Q1-Q3) and were compared using the Mann–Whitney test. P<0.05 was significant.

227

228

229

230

231

- There was no significant difference between the groups in the categorical clinical variables, such as associated comorbidities, previous pathological history of pain, history of PONV, physical status classification by ASA, degree of consciousness in the preoperative period, operation time, heart rate at admission to the operating room, and Aldrete and Kroulik score at departure from the operating room (Table 2).
- 238 Table 2. Clinical categorical variables.

Mariahla	Preg	Pregabalin		ebo	Dvolue
variable	n	%	n	%	P value
Comorbidities					
yes	9	34.6	9	34.6	4
no	17	65.4	17	65.4	I
PPH Pain					
yes	0	0	0	0	NA
no	26	100	26	100	NA
PONV					
yes	1	3.8	4	15.4	0.47
no	25	96.2	22	84.6	0.17
WING					
I	17	65.4	17	65.4	1
II	9	34.6	9	34.6	I
Preop awareness					
sleepy	1	3.8	1	3.8	
calm	18	69.2	17	65.4	0.99
anxious	7	26.9	8	30.8	
HR OR entry					
< 60 bpm	2	7.7	6	23.1	
60-90 bpm	17	65.4	15	57.7	0.36
> 90 bpm	7	26.9	5	19.2	
ALDRETE OR exit					
9	22	84.6	17	65.4	0.44
10	4	15.4	9	34.6	0.11

PPH: previous pathological history; PONV: postoperative nausea and vomiting; ASA: American Society of Anesthesiologists; Preoperative: preoperative period; HR: heart rate; OR: operating room. P<0.05 was significant ( $\chi^2$  test or Fisher's exact test).

# 239 There was no significant difference in the frequency of PONV between the groups at any

- time (Table 3).

# 242 Table 3. PONV episodes at the four times.

Variable	Pr	egabalin	Placebo	P valuo <sup>2</sup>	
	n	%	n %		
Nausea					
0 h	4	15.4	4 15.4	1	
6 h	5	19.2	4 15.4	0,50	
12 h	1	3.8	3 11.5	0,30	
24 h	6	23.1	6 23.1	1	
ANOVA repeated measures	<i>P value</i> <sup>1</sup> = 0.11		<i>P value</i> <sup>1</sup> = 0.71		
Vomiting					
0 h	2	7.7	0 0	0,25	
6 h	0	0	0 0	NA	
12 h	0	0	0 0	NA	
24 h	24 h 2 7.7		0 0	0,25	
ANOVA repeated measures	<i>P value</i> <sup>1</sup> = 0.26		NA		

T: time; 0 h: immediate postoperative period; h: hours.

<sup>1</sup> ANOVA for repeated measures of categorical data by the CATMOD procedure of SAS® software.

 $^2\,\chi^2$  test or Fisher's exact test. NA: not applicable. P<0.05 was significant.

- \_

- 254 There was no significant difference in VAS at rest or upon movement, at any time between
- the groups (Table 4). Within both groups, both at rest and in movement, there was a significant
- variation in pain control in the first 24 hours (Figs. 2 and 3).
- 257
- 258 Table 4. Evolution of VAS at rest and during movement at the four times.

Variable	Pregabalin	Placebo	P value <sup>2</sup>
VAS at rest (points)			
0 h	6.5 ±2.1	6.5 ± 1.9	0.99
6 h	5.9 ±1.8	6.0 ± 1.5	0.80
12 h	5.0 ±2.0	4.9 ± 1.4	0.87
24 h	3.3 ±2.4	3.1 ±2.0	0.71
ANOVA repeated measures	<i>P value</i> <sup>1</sup> < 0.0001	<i>P value</i> <sup>1</sup> < 0.0001	
Bonferroni multiple comparisons	(0 h, 6 h) ≠ (12 h, 24 h) and 12 h ≠ 24 h	(0 h, 6 h) ≠ (12 h, 24 h) and 12 h ≠ 24 h	
Moving VAS (points)			
0 h	7.5 ±2.1	7.2 ±2.0	0.69
6 h	6.8 ± 1.8	6.8 ± 1.5	0.87
12 h	5.4 ±2.1	5.7 ±1.5	0.49
24 h	3.9 ±2.4	4.0 ±1.9	0.90
ANOVA repeated measures	<i>P value</i> <sup>1</sup> < 0.0001	<i>P value</i> <sup>1</sup> < 0.0001	
Bonferroni multiple comparisons	(0 h, 6 h) ≠ (12 h, 24 h) and 12 h ≠ 24 h	(0 h, 6 h) ≠ (12 h, 24 h) and 12 h ≠ 24 h	

VAS: visual analog scale; 0 h: immediate postoperative period; h: hours.

<sup>1</sup> ANOVA for repeated measures within each group, time component. Bonferroni multiple comparisons test at the 5% level.

<sup>2</sup> Student's *t* test for independent samples.

259

260

261

262

263

264



Figure 2. VAS at rest over time according to group.





- There was no significant difference in the following variables between groups: frequency of adverse events in the first 24 hours after surgery, use of opioids after hospital discharge, use of opioid rescue medication or PONV in the first 24 hours after surgery, or development of postoperative chronic pain (Table 5).
- 282
- 283 Table 5. Postoperative variables by group.

Veriable	Pregabalin		Plac	Placebo		
	n	%	n	%	P Value	
Adverse events						
yes	5	19.2	7	26.9	0.51	
no	21	80.8	19	73.1	0.51	
Postdischarge opioid use						
yes	9	37.5	8	36.4	0.94	
no	15	62.5	14	63.6	0.94	
Total opioid rescue						
none	12	46.2	14	53.8		
one	11	42.3	8	30.8	0.74	
2 or 3	3	11.5	4	15.4		
PONV rescue						
yes	9	34.6	12	46.2	0.40	
no	17	65.4	14	53.8	0.40	
Opioid rescue						
yes	13	50.0	11	42.3	0.58	
no	13	50.0	15	57.7	0.56	
Chronic pain PO						
yes	6	25.0	9	40.9	0.25	
no	18	75.0	13	59.1	0.25	

PONV: postoperative nausea and vomiting; PO: postoperatively.

P<0.05 was significant ( $\chi^2$  test or Fisher's exact test).

- 285
- 286
- 287
- 288

## 289 Discussion

290 According to the Apfel criteria [6], the incidence of PONV in this study is moderate to high, 291 ranging from 40 to 80%, since only female patients and nonsmokers were included in this study, 292 factors that indicate aggressive multimodal treatment for the control of PONV symptoms [2,12]. 293 In addition, these patients received general anesthesia with volatile anesthetics and opioids, 294 which also increased the risk of PONV [12]. Adequate PONV control aims to avoid negative 295 postoperative repercussions such as fluid and electrolyte imbalance, wound dehiscence, 296 pulmonary aspiration, and prolonged hospital stay [4]. For this reason, advanced perioperative 297 recovery protocols have been increasingly introduced into anesthetic practice to promote early 298 recovery of patients by reducing the use of opioids, which in turn reduces PONV [1]. In the present 299 study, we administered pregabalin adjuvantly because there is evidence that this drug reduces 300 PONV [1,7]. Its mechanism of action in the prevention of PONV is not fully known, but it does 301 block voltage-gated calcium channels by reducing the release of excitatory neurotransmitters that 302 reduce postoperative inflammation. It has inhibitory action in the area postrema, which may help 303 to reduce intraoperative and postoperative opioid consumption [1].

304 Pregabalin doses, dosages for use, and types of surgeries it is used for are heterogeneous 305 [7]. This may explain the conflicting results of its use and suggests the need for more studies on 306 the subject [7]. Pregabalin doses have ranged from 50 mg to 600 mg per day, with different 307 dosages [1]. Some patients have used a dose of pregabalin preoperatively or postoperatively or 308 a dose administered preoperatively and another 12 hours later [7,13]. Patients who have received 309 higher doses of pregabalin have had less PONV, greater opioid-sparing effects, and greater 310 efficacy of pain control; however, they have had more side effects [7,13]. In contrast, Mishriky et 311 al. [14] found that a single preoperative dose of pregabalin was as effective as multiple doses and 312 that low doses (less than 75 mg) were as effective as high doses (300 mg) in terms of reducing 313 the consumption of morphine. For our study, we used 150 mg of pregabalin in the first 24 hours, 314 divided into a 75 mg tablet 2 hours before surgery and a 75 mg tablet 12 hours after the first dose 315 [15,16,17].

The total incidence of postoperative nausea in our study was 63.46%, all reported as mild, and the total incidence of postoperative vomiting was 7.69%. Previous studies [18, 19] reported that 5-HT3 receptor antagonists may be better antiemetics than anti-nausea agents, which may

319 explain the much lower incidence of vomiting (7.69%) than the incidence of nausea (63,46%) in 320 our study. At the four times studied (0 h, 6 hours, 12 hours, and 24 hours), there was no significant 321 difference in PONV with the use of pregabalin. The total incidence of the use of rescue antiemetic 322 medication in the first 24 hours after surgery was 40.38%, being slightly higher in the group that 323 did not use pregabalin (P = 0.40). In their meta-analysis, Grant et al. [1] demonstrated that 324 pregabalin reduces the incidence of nausea and vomiting and the administration of rescue 325 antiemetics within the first 24 hours after surgery performed under general anesthesia. However, 326 the same study emphasized that it is important to recognize that the studies included in their 327 meta-analysis treated PONV as a secondary outcome in their original study design, which may 328 limit the interpretation of the results [1]. This may be a reason for the different results compared 329 to our study. In addition, this meta-analysis [1] selected 18 studies that did not use any 330 prophylactic antiemetic medication during anesthesia. This finding may explain and limit the result 331 of the nonsuperiority of pregabalin compared to placebo found in our study, which used dual 332 antiemetic therapy in all patients based on the SAMBA protocol and the Apfel scale [6]. Two other 333 meta-analyses that evaluated the effect of pregabalin for the prevention of PONV were performed 334 in patients undergoing hysterectomy, with conflicting results [20, 21]. It is noteworthy that all of 335 their included studies treated PONV as a secondary outcome. Although Wang et al. [20] found a 336 positive effect of pregabalin at controlling PONV, they emphasized that the different doses of 337 pregabalin used and the heterogeneity of the studies were limiting factors of their meta-analysis. 338 Ni J et al. [21] explained that they did not conclude that there was a positive effect of pregabalin 339 in the control of PONV due to the need to obtain better-quality randomized controlled studies, as 340 their meta-analysis was limited by the heterogeneity and size of the studies (n<100), they 341 considered their results not clinically significant, especially in patients taking doses below 150 mg 342 of pregabalin. Regarding adverse events related to the use of pregabalin, in our study, 19% of 343 the patients reported sedation without other associated symptoms, but there was no significant 344 difference between groups (P = 0.51). Regarding this side effect of sedation, meta-analyses have 345 obtained similar results [1, 20, 21].

This study is limited by our understanding of the antiemetic mechanisms of action of pregabalin. More high-quality randomized, controlled, multicenter, double-blind clinical trials with

- 348 more evaluated patients, studying the antiemetic effect of pregabalin as the primary outcome, will
- be needed to validate the results of the present study.
- 350

### 351 Conclusions

- 352 The administration of 75 mg of pregabalin 2 hours before surgery and 12 hours after the first dose
- 353 showed no significant difference from placebo in the reduction of episodes of PONV in patients
- 354 undergoing breast reconstruction after bariatric surgery under general anesthesia. There were no
- 355 significant differences between the groups in the reduction of postoperative pain, the need for
- antiemetic and analgesic rescue medication, the development of postoperative chronic pain, or
- the number of adverse events with the use of pregabalin.
- 358

# 359 Acknowledgments

360

361 Conceptualization: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia Verçosa, Marcello
 362 Fonseca Salgado Filho.

- 363 Data curatorship: Rafael Reis Fernandes.
- 364 Formal analysis: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia Verçosa, Marcello
- 365 Fonseca Salgado Filho, Rosangela Aparecida Gomes Martins.

366 Investigation: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia Verçosa, Marcello Fonseca
 367 Salgado Filho.

- 368 Methodology: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia Verçosa, Marcello Fonseca
- 369 Salgado Filho, Rosangela Aparecida Gomes Martins, Alice Ramos Oliveira da Silva.
- 370 **Project management:** Rafael Reis Fernandes.
- 371 Validation: Ismar Lima Cavalcanti, Nubia Verçosa, Marcello Fonseca Salgado Filho.
- 372 Writing original draft: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia Verçosa,
- 373 Marcello Fonseca Salgado Filho.
- 374 Writing proofreading and editing: Rafael Reis Fernandes, Ismar Lima Cavalcanti, Nubia
- 375 Verçosa, Marcello Fonseca Salgado Filho.
- 376
- 377

# 378 References

- Grant MC, Betz M, Hulse M, Zorrilla-Vaca A, Hobson D, Wick E, et al. The effect of preoperative pregabalin on postoperative nausea and vomiting: a meta-analysis. Anesth Analg. 2016;123:1100-1107. <u>https://doi.org/10.1213/ANE000000000001404</u> PMID: 27464972
- GanTJ, Diemunsch P, Habib AS, Kovak A, Kranke P, Meyer TA, et al. Consensus
   guidelines for the management of postoperative nausea and vomiting. Anesth Analg.
   2014;118:85-113. https://doi.org/10.1213/ANE0000000000002 PMID: 24356162
- 386 3. Chatterjee S, Rudra A, Sengupta S. Current concepts in the management of
   postoperative nausea and vomiting. Anesthesiol Res Pract. 2011;748031.
   https://doi.org/10.1155/2011/748031 PMID: 22110499
- Silva AC, O'Ryan F, Poor DB. Postoperative nausea and vomiting (PONV) after
   orthognathic surgery: a retrospective study and literature review. J Oral Maxillofac Surg.
   2006;64:1385-1397. https://doi.org/10.1016/j.joms.2006.05.024 PMID: 16916674
- 392 5. Freedman BM, O'Hara E. Pregabalin has opioid-sparing effects following augmentation
  393 mammaplasty. Anesthet Surg J. 2008;28:421-424.
  394 https://doi.org/10.1016/j.asj.2008.04.004 PMID: 19083556
- Apfel CC, Philip BK, Cakmakkya OS, Shilling A, Leslie JB, Allard M, et al. Who is at risk
   for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiol. 2012;
   117:475-486. https://doi.org/10.1097/ALN.0b013e318267ef31 PMID: 22846680
- 398
  7. J Zhang, Ho KY, Wang Y. Efficacy of pregabalin in acute postoperative pain: a metaanalysis. Br J Anaesth. 2011;106:454-462. <u>https://doi.org/10.1093/bja/aer027</u> PMID:
  21357616
- 401 8. Doyle DJ, Hendrix JM, Garmon EH. American Society of Anesthesiologist Classification.
  402 Update: December 4, 2022. NBK441940. PMID: 28722969
- 403 9. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of
  404 chronic pain for ICD-11. Pain. 2015;156:1003-1007.
  405 https://doi.org/10.1097/j.pain.00000000000160 PMID: 25844555
- 406 10. Aldrete JA. The Post-anesthesia recovery score revisited. J Clin Anesth. 1995;7:89-91.
   407 <u>http://doi.org/10.1016/0952-8180(94)00001-k</u> PMID: 7772368

- 408 11. Stanish WM, Koch GG. "The use of CATMOD for repeated measurent analysis of
  409 categorical data", Proceedings of the ninth annual SAS users group international
  410 conference. Cary, NC: SAS Institute Inc. 1984;9:761-770.
- 411 12. Pierre S, Whelan R. Nausea and vomiting after surgery. Continuous Education in
  412 Anaesthesia Critical Care & Pain. 2013;13:28-32.
  413 https://doi.or/10.1093/bjaceaccp/mks046
- 414
  13. Chou R, Gordon DB, Leon-Casasola AO, Rosenberg JM, Bickler S, Brennan T, et al.
  415 Management of post-operative pain: a clinical practice guideline from the American Pain
  416 Society, the American Society of Regional Anesthesia and Pain Medicine, and the
  417 American Society of Anesthesiologists Committee on Regional Anesthesia, Executive
- 418
   Committee, and Administrative Council. J Pain. 2016;17:131-157.

   419
   https://doi.org/10.1016/j.jpain.2015.12.008
   PMID: 26827847
- 420 14. Mishriky BM, Waldron NH, Habib AS. Impact of pregabalin on acute and persistent
  421 postoperative pain: a systematic review and meta-analysis. Br J Anaesth 2015;114:10422 31. <u>https://doi.org/10.1093/bja/aeu293</u> PMID: 25209095
- 423 15. Agarwal A, Gautam S, Gupta D, Agarwal S, Singh PK, Singh U. Evaluation of a single
  424 dose of pregabalin for attenuation of post-operative pain after laparoscopic
  425 cholecystectomy. Br J Anaesth 2008;101:700-704. <u>https://doi.org/10.1093/bja/aen244</u>
  426 PMID: 18716003
- 431 17. George RB, Mckeen DM, Andreou P, Habib AS. A randomized placebo-controlled trial of
  432 two doses of pregabalin for postoperative analgesia in patients undergoing abdominal
  433 hysterectomy. Can J Anaesth. 2014;61:551-557. <u>https://doi.org/10.1007/s12630-014-</u>
  434 0147-4 PMID: 24668315
- 435 18. Park SK, Cho EJ. A randomized, double-blind trial of palonosetron compared with
  436 ondansetron in preventing postoperative nausea and vomiting after gynaecological

437		laparoscopic	surgery.	J	Int	Med	Res.	2011;39:	399–407.
438		https://doi.org/10.	1177/1473230	001103	<u>900207</u> F	PMID: 2167	72343		
439	19.	Candiotti KA, Birn	ibach DJ, Lub	arsky D	A, Nhuch	n F, Kamat	A, Koch W	/H, et al. Th	he impact
440		of pharmacogeno	mics on posto	operative	e nausea	and vomi	ting: does (	CYP2D6 a	llele copy
441		number and poly	morphisms at	ffect the	e succes	s or failure	e of ondan	setron pro	phylaxis?
442		Anesthesiology.	2005;102:54	43–549.	<u>https:</u>	//doi.org/1	0.1097/000	000542-20	<u>0503000-</u>
443		00011 PMID: 157	31591						
444	20.	Wang YM, Xia M	, Shan N, Yua	an P, Wa	ang DL,	Shao JH, e	et al. Prega	abalin can	decrease
445		acute pain and p	ostoperative	nausea	and von	niting in h	ysterectom	y: A meta	-analysis.
446		Medicine (Baltim	ore). 2017;96	6:e7714	. <u>https://</u>	<u>'doi.org/10</u>	.1097/MD.(	00000000	00007714
447		PMID: 28767611							
448	21.	Ni J, Jiang J, Mac	S, Sun RF. F	Pregaba	lin does	not decrea	se acute p	ain or post	operative
449		nausea and vom	iiting after hy	sterecto	omy: a n	neta-analy	sis. J Int I	Med Res.	2020;48:

450 300060520954720. <u>https://doi.org/10.1177/0300060520954720</u> PMID: 33334230





# Figure 1



Figure 2. VAS at rest over time according to group.

# Figure 2



Figure 3. VAS in motion over time by group.

Figure 3